Comparative Pharmacology
Head-to-head clinical analysis: DOXYCHEL HYCLATE versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCHEL HYCLATE versus TETRACHEL.
DOXYCHEL HYCLATE vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA binding to the mRNA-ribosome complex.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or IV every 12 hours on day 1, then 100 mg daily.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is 18–22 hours in patients with normal renal function; prolonged to 20–30 hours in severe renal impairment. Clinical context: Allows once- or twice-daily dosing.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Doxycycline hyclate is primarily excreted via the feces (approximately 90%) as an inactive chelated complex, with renal excretion accounting for about 10% of the dose. Biliary excretion is minimal.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic